Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10-15% of all childhood epilepsies. Only a handful of antiepileptic drugs (AEDs) are believed to be effective in CAE, and only two of these drugs (ethosuximide and valproate) are approved to treat absence seizures. Treatment becomes more complicated if the patient also suffers from co-occurring generalized tonic-clonic (GTC) seizures. Moreover, all AEDs currently used for CAE are associated with clinical shortcomings in efficacy, safety, and/or delivery. Thus, ample opportunity exists for new and improved alternatives, renewing developers’ interest in this space.

Questions Answered

  • What clinical end points and drug attributes are most influential in prescribing for CAE? How do currently available drugs like ethosuximide, valproate, and lamotrigine perform on these attributes?
  • What are the prevailing areas of unmet need and opportunity in the treatment of CAE?
  • Based on conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, and price are neurologists willing to make for a hypothetical new AED for CAE?

Markets covered: United States, United Kingdom, France, and Germany.

Primary Research: Survey of 60 U.S. neurologists and 31 European neurologists.

Key Drugs Covered: Ethosuximide, valproate, lamotrigine, levetiracetam, topiramate, zonisamide.

Key metrics included:

  • Target Product Profile (TPP) simulator based on conjoint analysis methodology.
  • Stated vs. derived importance of product attributes on prescribing behavior.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet needs in the indication and related indications.
  • Analysis of remaining drug development opportunities.

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis : Childhood Absence Epilepsy : US/EU
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Childhood Absence Epilepsy
      • Key Findings: Unmet Need in Childhood Absence Epilepsy and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Childhood Absence Epilepsy Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Offering More Complete Freedom from Treatment-Refractory Absences in CAE Patients
        • Opportunity: A Novel AED That Offers a Greater Reduction in the Frequency of Co-Occurring GTC Seizures in CAE Patients
        • Opportunity: New Therapies That Can Address Clinical Shortcomings of Drugs Currently Used to Treat CAE
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Childhood Absence Epilepsy Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Niyati Khetarpal, Ph.D

"Niyati Khetarpal  is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;


Related Reports

Epilepsy | Landscape & Forecast | Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the G7, according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient&rsqu...

View Details

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)

DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which...

View Details

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Generalized Onset Seizures (US)

DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS...

View Details

Epilepsy | Special Topics | Detailed, Expanded Analysis (US): Special Topics

Coming Soon – October 2019 More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet appr...

View Details